Last reviewed · How we verify

Avc — Competitive Intelligence Brief

Avc (SULFANILAMIDE) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: sulfanilamide. Area: Other.

marketed sulfanilamide Carbonic anhydrase 13 Other Small molecule Live · refreshed every 30 min

Target snapshot

Avc (SULFANILAMIDE) — Pharmobedient.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Avc TARGET SULFANILAMIDE Pharmobedient marketed sulfanilamide Carbonic anhydrase 13 1965-01-01
Ethamide ETHOXZOLAMIDE Pfizer marketed ethoxzolamide Carbonic anhydrase 1, Carbonic anhydrase 12, Carbonic anhydrase 13 1982-01-01
Azopt Azopt Alcon Research marketed Carbonic anhydrase 1, Carbonic anhydrase 12, Carbonic anhydrase 13
Meldane coumafos marketed Carbonic anhydrase 1, Carbonic anhydrase 12, Carbonic anhydrase 13

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (sulfanilamide class)

  1. Pharmobedient · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Avc — Competitive Intelligence Brief. https://druglandscape.com/ci/sulfanilamide. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: